Shots:

• Lupin is planning for EU approval of etanercept biosimilar in Mar 2020 with its expected launch in July 2020 in European markets- further planning its launch in the US and has also received approval in Japan in Mar 2019
• Additionally- Lupin has also signed an agreement with Mylan to launch its drug in Asia- Australia- Europe- and New Zealand
• Etanercept is a mAb targeting inflammatory cytokine tumor necrosis factor (TNF) and can be used to treat various forms of arthritis. Lupin also plans to file the approval of etanercept and pegfilgrastim biosimilars in the US in Q4 of the same year

Click here to­ read full press release/ article | Ref: Gabi | Image: Twitter